Evaluation of three experimental subunit vaccines against pneumonic pasteurellosis in cattle.
The objective of this study was to evaluate the efficacy of three Pasteurella haemolytica A1 derived experimental subunit vaccines against pneumonic pasteurellosis in cattle. The three vaccines were: (a) culture supernatant (CS) containing leukotoxin (Lkt), lipopolysaccharide (LPS) and capsular polysaccharide (CP); (b) sodium salicylate extract (SSE) containing iron regulated outer membrane proteins (IROMPs), LPS and CP; (c) and a combination of the above two. Vaccine efficacy was defined in terms of reduction in clinical and pneumonic lesion scores after intrapulmonic challenge with live P. haemolytica. The results indicate that the CS vaccine elicited antibodies against both Lkt and CP, while the SSE vaccine elicited antibodies against IROMPs and CP. Animals inoculated with the combination vaccine showed increased levels of antibodies against IROMPs, Lkt and CP. There was significant correlation between lung and serum antibodies against Lkt, CP and IROMPs. Animals that received the combination vaccine had significantly lower mean pneumonic lung score as compared to SSE and control groups. The animals which received CS vaccine had mean pneumonic lung score significantly lower than that of control group. A strong negative correlation existed between serum antibody levels against Lkt, IROMPs, CP and pneumonic lung scores. The results from this study demonstrate the usefulness of CS vaccine alone or in combination with SSE vaccine in bringing about optimal protection in vaccinated calves, against experimental pneumonic pasteurellosis.
Sreevatsan
S
S
Department of Clinical and Population Sciences, University of Minnesota, St. Paul 55108, USA.
Ames
T R
TR
Werdin
R E
RE
Yoo
H S
HS
Maheswaran
S K
SK
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D000942:Antigens, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002417:Cattle; D005069:Evaluation Studies as Topic; D005098:Exotoxins / Q000276:immunology / Q000627:therapeutic use; D008070:Lipopolysaccharides / Q000276:immunology / Q000627:therapeutic use; D008168:Lung / Q000382:microbiology; D016978:Mannheimia haemolytica / Q000276:immunology*; D012766:Pasteurellosis, Pneumonic / Q000276:immunology / Q000517:prevention & control*; D011135:Polysaccharides, Bacterial / Q000276:immunology / Q000627:therapeutic use
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D005098:Exotoxins; D008070:Lipopolysaccharides; D011135:Polysaccharides, Bacterial; C018579:leukotoxin